Trastuzumab-Pkrb (Intravenous Route)
Name: Trastuzumab-Pkrb (Intravenous Route)
- Trastuzumab-Pkrb Intravenous Route brand name
- Trastuzumab-Pkrb Intravenous Route injection
- Trastuzumab-Pkrb Intravenous Route used to treat
US Brand Name
Trastuzumab-pkrb injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or docetaxel and carboplatin) to treat HER2-overexpressing node-positive or node-negative (ER/PR negative or with one high risk feature) breast cancer.
Trastuzumab-pkrb injection is also used to treat HER2-overexpressing metastatic (cancer that has spread) breast cancer in patients who have received one or more chemotherapy treatments. It is also used together with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer.
Trastuzumab-pkrb prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).
Trastuzumab-pkrb is a monoclonal antibody. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by trastuzumab-pkrb, other effects will also occur. Some of these may be serious and must be reported to your doctor.
This medicine is to be given only by or under the direct supervision of your doctor.